Use of sulfonamide inhibitors of BCL-2 and BCL-xL to treat ophthalmic disease by selectively removing senescent cells
Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
1. A method of treating an ophthalmic disease or disorder that is not a cancer in a subject,
the method comprising administering in or around an eye of the subject a pharmaceutical composition that contains an effective amount of a compound that inhibits Bcl-2 and Bcl-xL in a pharmaceutically acceptable excipient,
wherein the compound is (R)—N-(4-(4-(3-(2-(4-chlorophenyl)-1-isopropyl-5-methyl-4-(methylsulfonyl)-1H-pyrrol-3-yl)-5-fluorophenyl)piperazin-1-yl)phenyl)-4-((4-(4-hydroxypiperidin-1-yl)-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide (BM-1197) or a salt thereof.
2. The method of claim 1 , which is a method of treating age-related macular degeneration (AMD).
3. The method of claim 1 , which is a method of treating glaucoma.
4. The method of claim 1 , which is a method for preventing or delaying vision loss.
5. The method of claim 1 , wherein the composition is administered to the eye by intraocular injection.
6. The method of claim 1 , wherein the composition is administered to the eye by intravitreal injection.
7. The method of claim 1 , whereby p16 positive senescent cells in the eye that are causing one or more symptoms of the ophthalmic disease or disorder are removed from the eye.
8. The method of claim 1 , wherein the pharmaceutical composition delays disorganization of type IV collagen in the eye.
9. The method of claim 1 , wherein the pharmaceutical composition is administered in a therapeutically effective course of therapy that includes a period of treatment followed by a non-treatment interval of at least two weeks.
10. The method of claim 1 , wherein administration of the pharmaceutical composition to the eye as a single dose is effective in decreasing severity or delaying progression of one or more symptoms of the ophthalmic disease for at least two weeks.
11. A method of treating an ophthalmic disease or disorder in a subject who does not have cancer,
the method comprising administering intraocularly into an eye of the subject that is affected with the disease or disorder an effective amount of the following compound, or a pharmaceutically acceptable salt thereof
12. A method of removing senescent cells from an eye of a subject in need thereof,
wherein the senescent cells are identifiable as p16 positive cells that are not cancer cells,
the method comprising contacting the senescent cells in the eye with an effective amount of (R)—N-(4-(4-(3-(2-(4-chlorophenyl)-1-isopropyl-5-methyl-4-(methylsulfonyl)-1H-pyrrol-3-yl)-5-fluorophenyl)piperazin-1-yl)phenyl)-4-((4-(4-hydroxypiperidin-1-yl)-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide, or a pharmaceutically acceptable salt thereof.
13. The method of claim 12 , wherein the p16 positive senescent cells are causing or mediating one or more symptoms of an ophthalmic disease or disorder in the eye.
14. The method of claim 12 , whereby one or more symptoms of an ophthalmic disease or disorder in the eye are decreased in severity or delayed in progression consequent to treating the eye to remove senescent cells.
15. The method of claim 12 , further comprising determining whether positive senescent cells have been removed from the eye of the subject in which senescent cells have been contacted with said benzenesulfonamide.
16. The method of claim 12 , further comprising examining the subject to determine whether symptoms of an ophthalmic disease or disorder are decreased in severity or delayed in progression consequent to treating the eye to remove senescent cells.